stockrow
Saturday 7 November 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
1.98
0.11
−5.26%
Follow MCRB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 22.21 |
+8 more quarters Free account |
P/S ratio |
15.74 | 40.67 | 55.89 | 89.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 122.63 | |
P/Operating CF |
(3.19) | (3.42) | (5.20) | (8.96) | |
P/B ratio |
1.57 | 2.22 | 3.21 | 2.98 | |
Price to Tangible BV |
1.57 | 2.22 | 3.21 | 2.98 | |
EV/Sales |
55.72 | 86.82 | 103.66 | 128.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.85) | (3.19) | (3.74) | 168.80 | |
EV/FCF |
(1.86) | (3.19) | (3.74) | 175.40 | |
Quick Ratio |
1.45 | 2.04 | 1.55 | 2.40 | |
Current Ratio |
1.65 | 2.11 | 1.65 | 2.56 | |
Net Debt/EBITDA |
1.12 | 0.76 | 1.48 | 2.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF/Net income |
0.64 | (4.89) | 0.82 | 0.96 | |
Capex/Depreciation |
0.11 | 0.02 | 0.00 | 0.19 | |
Research and Development Expense of Revenue |
943.00% | 1,241.98% | 3,685.75% | 2,667.58% | |
Selling, General and Administrative Expense of Revenue |
918.72% | 959.38% | 2,254.19% | 1,721.23% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
313.49% | 236.28% | 493.30% | 730.37% | |
Graham Net Nets |
(0.30) | (0.32) | (0.70) | (0.34) | |
Graham Number |
0.00 | 0.00 | 0.00 | 8.67 | |
Earnings Yield |
(149.30%) | (30.80%) | (58.29%) | 4.50% | |
Free Cash Flow Yield |
(190.50%) | (66.93%) | (49.64%) | 0.82% | |
Revenue per Share |
0.06 | 0.08 | 0.04 | 0.05 | |
Operating CF per Share |
(1.05) | (2.31) | (1.71) | (1.66) | |
Capex per Share |
0.01 | 0.00 | 0.00 | 0.02 | |
Free Cash Flow per Share |
(1.04) | (2.31) | (1.71) | (1.64) | |
Cash per Share |
1.76 | 1.61 | 3.11 | 5.17 | |
Shareholders Equity per Share |
2.14 | 3.56 | 2.77 | 4.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.14 | 3.56 | 2.77 | 4.99 | |
Free Cash Flow |
(10.42) | (22.38) | (16.36) | (14.53) | |
Working Capital |
13.53 | 22.32 | 12.49 | 30.05 | |
Capital Expenditures |
0.05 | 0.01 | — | 0.18 | |
Net Current Asset Value |
(10.11) | (24.71) | (59.28) | (44.60) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.09) | (0.02) | 0.00 | (0.41) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.73 | 13.08 | 1.50 | 1.29 | |
Average Payables |
1.57 | 1.69 | 2.25 | 2.88 | |
Average Assets |
104.68 | 122.69 | 140.90 | 139.00 | |
Average Common Equity |
32.53 | 33.74 | 38.48 | 29.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026